Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322903 | 0.87 | DPP4 (0.42) | F2DPP4 | |
| SCHEMBL12986835 | 0.85 | F2 (0.38) | F2DPP4PRSS1F10LMNA | |
| SCHEMBL12986829 | 0.85 | F2 (0.38) | F2DPP4PRSS1F10LMNA | |
| SCHEMBL12985686 | 0.85 | F2 (0.38) | F2DPP4PRSS1F10LMNA | |
| SCHEMBL12989245 | 0.85 | F2 (0.38) | F2DPP4PRSS1F10LMNA | |
| SCHEMBL15610636 | 0.85 | F2 (0.38) | F2DPP4PRSS1F10LMNA | |
| Hydrochloric Acid SCHEMBL15610585 | 0.84 | F2 (0.38) | F2DPP4PRSS1F10LMNA | |
| Hydrochloric Acid SCHEMBL15610364 | 0.84 | F2 (0.38) | F2DPP4PRSS1F10LMNA | |
| Hydrochloric Acid SCHEMBL20491373 | 0.84 | F2 (0.38) | F2DPP4PRSS1F10LMNA | |
| SCHEMBL4441005 | 0.84 | DPP4 (0.44) | DPP4PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | F2 3514/4885DPP4 532/4885PRSS1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.